Brought to you by 
Allergan sublicenses neuropathic pain agent to BMS
12 Jun 2013
Executive Summary
Pharmaceutical and device firm Allergan has granted Bristol-Myers Squibb an exclusive worldwide sublicense to develop, manufacture, and sell its Phase II-ready oral neuropathic pain candidate AGN209323 (also called EHT/AGN0001) plus EHT/AGN0002, which is in preclinical studies for pain and neurodegeneration, and other back-up compounds. The deal covers all potential indications except ophthalmology--specifically locally delivered drugs to the eye--to which Allergan retains rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Allergan sublicenses neuropathic pain agent to BMS
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice